http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 22 Sep 2026 18:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology platform http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092057.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/Press+Releases/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html <p><strong id="dateline">CALGARY, AB AND VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / September 22, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>) (Frankfurt:<strong>W1H</strong>, <strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>") and Redwood AI Corp. (CSE:<strong>AIRX</strong>)(OTCQB:<strong>RDWCF</strong>)(Frankfurt:<strong>Y0N</strong>, WKN:<strong>A422EZ</strong>) ("<strong>Redwood AI</strong>") are pleased to announce that Onco, as lead applicant, together with Redwood AI, Canada's Michael Smith Genome Sciences Centre ("<strong>GSC</strong>") and Centre de recherche du CHU de Québec-Université Laval ("<strong>CRCHUQ</strong>"), as co-applicants, have been awarded a competitive grant under the Digital Health Innovation Fund (<strong>DHIF</strong>), administered by the Terry Fox Research Institute (<strong>TFRI</strong>), to support the development and advancement of SynoGraph, an AI-driven oncology http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+and+Redwood+AI+Secure+Terry+Fox+Research+Institute+Grant+to+Advance+AI-Powered+SynoGraph%28TM%29+Oncology+Platform/27092064.html Tue, 22 Sep 2026 18:00:00 -0400 AIRX ONNVF RDWCF http://www.streetinsider.com/Management+Changes/Onco-Innovations+CMO+discusses+PNKP+cancer+drug+on+podcast/27045388.html <p>Onco-Innovations Ltd. (CBOE CA: ONCO, OTCQB: ONNVF), a clinical-stage oncology company based in Calgary, Canada, featured its Chief Medical Officer, Dr. Islam Mohamed, in a recent episode of The BioMedWire Podcast, distributed by IBN.</p> <p>Mohamed discussed the company's lead drug candidate, ONC010, which targets polynucleotide kinase phosphatase (PNKP), a DNA repair enzyme. According to Mohamed, no other clinical-stage program targeting PNKP currently exists. Onco-Innovations holds exclusive worldwide rights to foundational PNKP inhibitor patents from the University of Alberta, along with an exclusive sublicense to an accompanying nanoparticle delivery platform.</p> <p>Mohamed described ONC010 as combining two selectivity mechanisms. The first is biological, using http://www.streetinsider.com/Management+Changes/Onco-Innovations+CMO+discusses+PNKP+cancer+drug+on+podcast/27045388.html Thu, 10 Sep 2026 08:00:24 -0400 ONNVF http://www.streetinsider.com/Press+Releases/IBN+Announces+Latest+Episode+of+The+BioMedWire+Podcast+Featuring+Dr.+Islam+Mohamed%2C+Chief+Medical+Officer+of+Onco-Innovations+Ltd./27045337.html <p><em>Disseminated on behalf of </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jhZyl3Y8lGvzJZMx3_h1a7CJcolH8DYm-yQqyJ8L8PwY5qSRlbXmUr9W56QyJfWWdNL7ebLyR5yh-ibctDM1a9rlf9mp7o0oaW18ZfjArJsgJS3Q81Xl-bEO4j6s6_T-" rel="nofollow" target="_blank"><em>Onco-Innovations Ltd.</em></a><em>, may include paid advertisements.</em></p> <p>AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xp3tjAU1ukH2wngey9SWWjdde68BbQKz96-ewvC1MAmtFjHU0HKTTFHuedDDnvf5lkMxpiZQ7CTeCrYOgGvFa7hqCd2YX7rWm_XQVzdgepk=" rel="nofollow" target="_blank">IBN</a> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bO7RYK97gAJ37tismQcuJ0yT9t2LIL0bI7RN_HAsQ56T0Itcywz7kuFygmVK11qRNmJHhY-Utwlf_J7Bn9Y-36LXlqIOVpJDWyKzCLaZPj8=" rel="nofollow" target="_blank">IBN</a>, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sPw5YiA3oXo-5YsPR6d42-UzN4pFHgSgbTcehE_RLazBp5kmyyc_diAtU6lgAuTUFh7noBcOeNQjWLY8qbiy6RwkEgsEOumTOSjpV8KVm70=" rel="nofollow" target="_blank">The BioMedWire Podcast</a> as part of its sustained effort to provide specialized content distribution via widespread syndication channels.</p> <p>The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The http://www.streetinsider.com/Press+Releases/IBN+Announces+Latest+Episode+of+The+BioMedWire+Podcast+Featuring+Dr.+Islam+Mohamed%2C+Chief+Medical+Officer+of+Onco-Innovations+Ltd./27045337.html Thu, 10 Sep 2026 08:00:00 -0400 ONNVF http://www.streetinsider.com/Globe+Newswire/IBN+Announces+Latest+Episode+of+The+BioMedWire+Podcast+Featuring+Dr.+Islam+Mohamed%2C+Chief+Medical+Officer+of+Onco-Innovations+Ltd./27045337.html <p><em>Disseminated on behalf of </em><a target="_blank" href="https://www.globenewswire.com/Tracker?data=jhZyl3Y8lGvzJZMx3_h1a7CJcolH8DYm-yQqyJ8L8PwY5qSRlbXmUr9W56QyJfWWdNL7ebLyR5yh-ibctDM1a9rlf9mp7o0oaW18ZfjArJsgJS3Q81Xl-bEO4j6s6_T-" rel="nofollow" target="_blank"><em>Onco-Innovations Ltd.</em></a><em>, may include paid advertisements.</em></p> <p>AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=Xp3tjAU1ukH2wngey9SWWjdde68BbQKz96-ewvC1MAmtFjHU0HKTTFHuedDDnvf5lkMxpiZQ7CTeCrYOgGvFa7hqCd2YX7rWm_XQVzdgepk=" rel="nofollow" target="_blank">IBN</a> – <a target="_blank" href="https://www.globenewswire.com/Tracker?data=bO7RYK97gAJ37tismQcuJ0yT9t2LIL0bI7RN_HAsQ56T0Itcywz7kuFygmVK11qRNmJHhY-Utwlf_J7Bn9Y-36LXlqIOVpJDWyKzCLaZPj8=" rel="nofollow" target="_blank">IBN</a>, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of <a target="_blank" href="https://www.globenewswire.com/Tracker?data=sPw5YiA3oXo-5YsPR6d42-UzN4pFHgSgbTcehE_RLazBp5kmyyc_diAtU6lgAuTUFh7noBcOeNQjWLY8qbiy6RwkEgsEOumTOSjpV8KVm70=" rel="nofollow" target="_blank">The BioMedWire Podcast</a> as part of its sustained effort to provide specialized content distribution via widespread syndication channels.</p> <p>The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The http://www.streetinsider.com/Globe+Newswire/IBN+Announces+Latest+Episode+of+The+BioMedWire+Podcast+Featuring+Dr.+Islam+Mohamed%2C+Chief+Medical+Officer+of+Onco-Innovations+Ltd./27045337.html Thu, 10 Sep 2026 08:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Enters+into+LOI+with+Ifowonco+for+Exclusive+Option+and+Worldwide+Licence+to+LAG-3+Small-Molecule+Inhibitor+Program/26951457.html <p><strong id="dateline">CALGARY, AB / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 19, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a non-binding Letter of Intent ("<strong>LOI</strong>") with Ifowonco Informatics Incorporated ("<strong>Ifowonco</strong>") as an initial step toward negotiating a definitive agreement that would, if completed, grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 ("<strong>LAG-3</strong>") (the "<strong>LAG-3 Program</strong>").</p><p>The proposed collaboration is intended to combine Ifowonco's novel oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) http://www.streetinsider.com/Press+Releases/Onco-Innovations+Enters+into+LOI+with+Ifowonco+for+Exclusive+Option+and+Worldwide+Licence+to+LAG-3+Small-Molecule+Inhibitor+Program/26951457.html Wed, 19 Aug 2026 18:40:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Enters+into+LOI+with+Ifowonco+for+Exclusive+Option+and+Worldwide+Licence+to+LAG-3+Small-Molecule+Inhibitor+Program/26951457.html <p><strong id="dateline">CALGARY, AB / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / August 19, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong>WKN:A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce that it has entered into a non-binding Letter of Intent ("<strong>LOI</strong>") with Ifowonco Informatics Incorporated ("<strong>Ifowonco</strong>") as an initial step toward negotiating a definitive agreement that would, if completed, grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 ("<strong>LAG-3</strong>") (the "<strong>LAG-3 Program</strong>").</p><p>The proposed collaboration is intended to combine Ifowonco's novel oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Enters+into+LOI+with+Ifowonco+for+Exclusive+Option+and+Worldwide+Licence+to+LAG-3+Small-Molecule+Inhibitor+Program/26951457.html Wed, 19 Aug 2026 18:40:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 10, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient ("<strong>API</strong>") supporting the Company's lead oncology program, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational http://www.streetinsider.com/Press+Releases/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html Fri, 10 Jul 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / July 10, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the successful completion of its analytical reference standard preparation program for A83B4C63, the active pharmaceutical ingredient ("<strong>API</strong>") supporting the Company's lead oncology program, ONC010 (the "<strong>PNKP Inhibitor Technology</strong>").</p><p>The reference standard program, which was completed in collaboration with Dalton Pharma Services, included the preparation, purification, analytical evaluation and quality assessment of highly characterized A83B4C63 material intended for use as a reference standard in future analytical testing programs. Reference standards serve as foundational http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Completes+Analytical+Reference+Standard+Preparation+Program+for+ONC010%E2%80%99s+API/26758171.html Fri, 10 Jul 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 30, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated June 23, 2026, the initiation of polymer process development and analytical characterization activities being conducted by Nanosoft Polymers ("Nanosoft") in support of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Current activities include polymer synthesis optimization, characterization methodology development, molecular weight assessment, polydispersity evaluation, purification strategy refinement and manufacturing scalability assessments. These efforts are intended to establish a robust and reproducible http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html Tue, 30 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 30, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong>W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") is pleased to announce, further to its news release dated June 23, 2026, the initiation of polymer process development and analytical characterization activities being conducted by Nanosoft Polymers ("Nanosoft") in support of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase ("PNKP") inhibitor.</p><p>Current activities include polymer synthesis optimization, characterization methodology development, molecular weight assessment, polydispersity evaluation, purification strategy refinement and manufacturing scalability assessments. These efforts are intended to establish a robust and reproducible http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Polymer+Process+Development+and+Characterization+Program+for+ONC010/26715062.html Tue, 30 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong> W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010, the Company's lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modeling, dose selection and regulatory submissions.</p><p>The studies are being conducted by Nucro-Technics, one of Canada's leading providers of IND-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat http://www.streetinsider.com/Press+Releases/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html Fri, 26 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html <p><strong id="dateline">VANCOUVER, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / June 26, 2026 / </strong>Onco-Innovations Limited (CBOE CA:<strong>ONCO</strong>)(OTCQB:<strong>ONNVF</strong>)(Frankfurt:<strong> W1H</strong>,<strong> WKN: A3EKSZ</strong>) ("<strong>Onco</strong>" or the "<strong>Company</strong>") announces the initiation of hepatocyte and liver microsome metabolism studies for ONC010, the Company's lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modeling, dose selection and regulatory submissions.</p><p>The studies are being conducted by Nucro-Technics, one of Canada's leading providers of IND-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat http://www.streetinsider.com/ACCESS+Newswire/Onco-Innovations+Initiates+Three-Species+Hepatocyte+and+Microsome+Metabolism+Studies+for+ONC010/26700135.html Fri, 26 Jun 2026 18:00:00 -0400 ONNVF http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Press+Releases/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html <p>AUSTIN, Texas, June 26, 2026 (GLOBE NEWSWIRE) -- via <a target="_blank" href="https://www.globenewswire.com/Tracker?data=mWF3epHXD4YQG_X6PH-rrUfOUN-LH2QBBy1B9GNhTpldUN5w9PZKaX6uykmo6vdZ5s3m2I__Vsa4zPi6hUXzrZvAzxvEKz-RJE9Xl8uyMDo=" rel="nofollow" target="_blank">IBN</a> – NetworkNewsAudio announces the Audio Press Release (APR) titled “Next-Generation DNA Repair Therapies Open New Frontiers in Oncology,” featuring <a target="_blank" href="https://www.globenewswire.com/Tracker?data=MV9bj8X2YOa436cDfbC3zQpGWr51IIaYT_Y652PVa-VudfPtcvCLymOhyW1pPiaxhFLZh2ScNZAQ4QpZixOUllhdizcwXMZPt7KWfO6mDo7_9qsS5Nhdfx9Do3LKdWlkEeodOkDGv2TfgqwQAlWNgy2Uqytexel16Vkkic-bEN0=" rel="nofollow" target="_blank">Onco-Innovations Limited</a> (CBOE CA: ONCO) (OTCQB: ONNVF).</p> <p>To hear the NetworkNewsAudio version, visit <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOCkQNlJ6rWdeEuKK58qu61kP4NUOK1a_m6cqvJ-VuK10cVK5lrJAMzMosb8OHy2jb220-Qb09uvUdA9JJBKRJCI=" rel="nofollow" target="_blank">https://ibn.fm/6BxDD</a> </p> <p>To read the original editorial, visit: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=-m0xFfRxz6RpjksYmdKrOP6rRzcRYs0oI7pcEukazCFG2cCGNiTeAsUN_zYQfYGRy3SchJofZN0o4OaocEn1YTXPxYe0Xxj4UQHFkZ0eZ4k=" rel="nofollow" target="_blank">https://ibn.fm/Lhc3W</a></p> <p style="padding-left:40px;">Most races in oncology drug development are crowded. PARP inhibitors, PD-1 checkpoints and CDK4/6 inhibitors all attracted dozens of competitors as their commercial potential became clear. PNKP inhibitors are different. The target has http://www.streetinsider.com/Globe+Newswire/NetworkNewsAudio+Announces+Audio+Press+Release+%28APR%29+Discussing+the+Development+of+PNKP+Inhibitors+in+Oncology+Drug+Development/26695314.html Fri, 26 Jun 2026 08:30:00 -0400 O.69703487 ONCO ONCO.NE ONNVF